PMID- 30635175
OWN - NLM
STAT- MEDLINE
DCOM- 20200414
LR  - 20221207
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 19
IP  - 2
DP  - 2019 Apr
TI  - Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A 
      Retrospective Comparison of Efficacy and Safety Profiles.
PG  - e306-e318
LID - S1526-8209(18)30638-4 [pii]
LID - 10.1016/j.clbc.2018.12.004 [doi]
AB  - BACKGROUND: Single-agent gemcitabine is a moderately effective compound in 
      metastatic breast cancer (mBC) treatment. Carboplatin is frequently used in 
      addition to gemcitabine to improve tumor responses, but with an unclear effect on 
      survival outcomes. In this study we evaluated the antitumor efficacy and safety 
      profiles of gemcitabine and carboplatin-gemcitabine in mBC patients. PATIENTS AND 
      METHODS: We retrospectively collected data on patients treated between April 2012 
      and February 2018 with gemcitabine 800 mg/m(2)or carboplatin at an area under the 
      curve of 2 with gemcitabine 800 mg/m(2), given on days 1 and 8 every 21 days. We 
      compared progression-free survival (PFS), objective response rate (ORR), overall 
      survival, and incidence of adverse events (AEs) in the 2 cohorts. RESULTS: Of 163 
      consecutive patients who met the inclusion criteria, 75 received gemcitabine and 
      88 carboplatin-gemcitabine. Patients in the combination cohort had received a 
      lower number of previous chemotherapy lines (2 vs. 3), and were less likely to 
      have received carboplatin (9 patients [10%] vs. 34 patients [45%]; P < .0001). We 
      found no PFS differences in carboplatin-gemcitabine and gemcitabine cohorts (4.24 
      vs. 4.61 months; adjusted hazard ratio, 0.98; P = .92), whereas the combination 
      was associated with a trend toward higher ORR (18 patients [20.4%] vs. 8 patients 
      [10.6%]; P = .089) and with significantly higher incidence of Grade 3/4 
      neutropenia (30 patients [34%] vs. 5 patients [6.6%]; P < .0001). CONCLUSION: 
      Using carboplatin in addition to gemcitabine is associated with more hematologic 
      AEs but not with better PFS. Although single-agent gemcitabine remains a 
      treatment option for heavily pretreated mBC patients, finding biomarkers of 
      response to platinum salts might help to identify patients more likely to benefit 
      from carboplatin-gemcitabine.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Vernieri, Claudio
AU  - Vernieri C
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy; Fondazione Istituto FIRC di Oncologia 
      Molecolare (IFOM), Milan, Italy. Electronic address: 
      claudio.vernieri@istitutotumori.mi.it.
FAU - Prisciandaro, Michele
AU  - Prisciandaro M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Milano, Monica
AU  - Milano M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Cona, Maria Silvia
AU  - Cona MS
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Maggi, Claudia
AU  - Maggi C
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Brambilla, Marta
AU  - Brambilla M
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Mennitto, Alessia
AU  - Mennitto A
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Fabbroni, Chiara
AU  - Fabbroni C
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Fare, Elena
AU  - Fare E
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Cresta, Sara
AU  - Cresta S
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Celio, Luigi
AU  - Celio L
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Mariani, Gabriella
AU  - Mariani G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Bianchi, Giulia
AU  - Bianchi G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - Capri, Giuseppe
AU  - Capri G
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale per lo Studio e 
      la Cura dei Tumori, Milan, Italy; Oncology and Haemato-Oncology Department, 
      University of Milan, Milan, Italy. Electronic address: 
      filippo.debraud@istitutotumori.mi.it.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20181212
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Antineoplastic Agents)
RN  - 0W860991D6 (Deoxycytidine)
RN  - BG3F62OND5 (Carboplatin)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Carboplatin/*administration & dosage/adverse effects
MH  - Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives
MH  - Female
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Middle Aged
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Gemcitabine
OTO - NOTNLM
OT  - Adverse events
OT  - Metastatic breast cancer
OT  - Objective response rate
OT  - Overall survival
OT  - Progression-free survival
EDAT- 2019/01/13 06:00
MHDA- 2020/04/15 06:00
CRDT- 2019/01/13 06:00
PHST- 2018/09/08 00:00 [received]
PHST- 2018/10/26 00:00 [revised]
PHST- 2018/12/04 00:00 [accepted]
PHST- 2019/01/13 06:00 [pubmed]
PHST- 2020/04/15 06:00 [medline]
PHST- 2019/01/13 06:00 [entrez]
AID - S1526-8209(18)30638-4 [pii]
AID - 10.1016/j.clbc.2018.12.004 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. 
      Epub 2018 Dec 12.